LL-37: the only human cathelicidin antimicrobial peptide

LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino-acid cationic amphipathic helix generated from the hCAP18 precursor (CAMP gene). it is one of the most-studied human innate-immunity peptides, with broad direct antimicrobial activity and a deep portfolio of host-response effects ranging from leukocyte recruitment to wound healing. it is not an approved drug, and its translational story is shaped by a pro- vs anti-inflammatory paradox that makes context everything.

what is LL-37?

LL-37 is the single human cathelicidin antimicrobial peptide. the name reflects the leading Leu-Leu sequence and the 37-amino-acid length. it is generated from the precursor hCAP18 by proteinase 3 cleavage, primarily in neutrophil-associated contexts, and adopts an alpha-helical conformation when it interacts with a membrane.

LL-37 is produced by multiple innate barrier and immune-cell compartments. neutrophils store hCAP18 in granules and release the processed peptide on activation. monocytes and macrophages express it; epithelial cells in skin, airway, and gut express it; and keratinocytes induce it in response to vitamin D signaling. this distribution explains why LL-37 functions as a bridge between barrier defense and immune orchestration rather than as a narrow direct microbicide [1].

as a cationic amphipathic peptide, LL-37's biophysical signature is straightforward. positive charges on the helix are attracted to negatively charged microbial-membrane lipids, the hydrophobic face inserts into the lipid bilayer, and depending on local conditions the peptide produces toroidal-pore-like or carpet-like membrane destabilization. the same biophysics is mechanistically why microbial selectivity exists and why mammalian membrane composition is comparatively spared at therapeutically relevant peptide concentrations.

how does it work?

LL-37 has two intertwined mechanism layers: direct antimicrobial activity through membrane disruption and biofilm interference, and host immune modulation through chemotaxis at FPR2 (FPRL1), endotoxin neutralization, intracellular bacterial killing via autophagy (with vitamin D), and effects on keratinocyte migration and angiogenesis. it can simultaneously suppress and amplify inflammation depending on context.

the direct antimicrobial layer covers broad-spectrum activity across Gram-positive and Gram-negative bacteria, antifungal activity against Candida species (including biofilm models), and reported antiviral activity against multiple enveloped viruses including HIV, influenza A, and SARS-CoV-2 [2]. the anti-biofilm activity is particularly clinically interesting because LL-37 inhibits biofilm formation at sub-MIC concentrations in important pathogens such as Pseudomonas aeruginosa, and it can also affect pre-formed biofilms and quorum-sensing gene regulation [3]. this matters for chronic wound and device-related infection biology, where biofilm is the major treatment failure mode.

the immunomodulatory layer is broader. LL-37 is chemotactic for neutrophils, monocytes, and T cells, primarily through the formyl peptide receptor FPR2/FPRL1. it can neutralize LPS and reduce downstream TLR4 inflammatory signaling, including NF-kB-dependent cytokine programs, which is the basis for the "anti-endotoxin" framing in rat gram-negative sepsis models. it promotes keratinocyte migration via EGFR transactivation pathways and contributes to angiogenesis and tissue repair, which is the basis for the wound-healing framing [4]. Liu and colleagues' 2006 Science paper established a vitamin D / cathelicidin / TLR axis that connects vitamin D status to innate antimicrobial autophagy programs, which has become one of the most cited mechanistic anchors in the LL-37 literature [5].

the central nuance is the pro- vs anti-inflammatory paradox. in LPS-driven settings LL-37 can suppress pro-inflammatory cytokines, but in other contexts it can amplify inflammatory pathways, recruit leukocytes, or trigger NET and inflammasome-adjacent activity. LL-37 is therefore a context-dependent immunomodulator, not a simple anti-inflammatory; benefit or harm depends on disease phase, compartment, and dosing.

what does the evidence show?

LL-37's evidence is strongest in preclinical infection and wound-healing models, especially anti-biofilm and chronic-wound paradigms, with translational extensions to MRSA, tuberculosis, urinary tract infection, and diabetic foot ulcers. human interventional data are limited: a small completed intratumoral melanoma trial and a registered Phase 2 diabetic-foot-ulcer cream trial are the main controlled-clinical touchpoints.

on the infection side, LL-37 has in-vitro and animal evidence in MRSA models including infected-wound and pneumonia paradigms, with antibiofilm and immunomodulatory effects often stronger than direct low-dose planktonic kill. the tuberculosis angle is mechanistically important: LL-37 is induced in TB-relevant cells, and the vitamin D / TLR pathway raises cathelicidin-dependent intracellular killing, which supports mechanistic plausibility for host-directed adjunct strategies. the chronic-wound angle is also strong on rationale (antibiofilm signaling plus wound-healing effects) but limited by a real translational obstacle: chronic-wound fluids can inhibit LL-37 activity through glycosaminoglycan complexing and proteolysis, so simple "add LL-37 to a wound" interventions have to overcome the local inhibitory environment.

on the wound-healing side, a registered Phase 2 clinical trial of LL-37 cream for diabetic foot ulcers exists (NCT04098562), and preclinical and translational studies support an antimicrobial-plus-healing rationale. burn and complex-wound relevance is high on rationale (angiogenesis, epithelial migration, antibiofilm) but direct large high-quality burn-specific RCT evidence remains limited.

on the cancer side, LL-37 has a complex bidirectional story. anti-tumor signals have been reported in colon, gastric, and pancreatic models, including some immune-reprogramming effects. pro-tumor associations have been reported in ovarian, breast, lung, melanoma, and squamous-cell carcinoma contexts, including migration, stromal recruitment, and proliferative signaling. a small intratumoral melanoma trial (NCT02225366) has been completed. on respiratory defense, LL-37 contributes to innate airway antimicrobial activity, has a context-dependent role in cystic fibrosis (abundant in CF airway fluid but functionally inhibited by complexing and proteolysis), and has in-vitro and biophysical data interfering with SARS-CoV-2 spike-mediated entry, although human clinical SARS-CoV-2 data remain early and mixed [6].

regulatory and supply status

LL-37 is not an FDA-approved drug. registered clinical work includes a completed small intratumoral melanoma trial and a Phase 2 LL-37 cream trial for diabetic foot ulcers. outside of those registered programs, consumer-facing supply runs through grey-market peptide vendors with no approval, no validated dose-finding, and no standardized product quality.

the regulatory picture is straightforward. no LL-37 product has FDA approval for any indication. the most credible recent translational programs are the diabetic foot ulcer cream Phase 2 trial and the small completed intratumoral melanoma trial; neither has produced an approved product. community discussion of subcutaneous microgram-range LL-37 protocols circulates online but is not derived from FDA-cleared dose-finding, does not have the quality framework of approved drugs, and frequently relies on vendor and forum sources rather than peer-reviewed clinical work.

the practical implication for any learner is that "LL-37 as a community peptide" and "LL-37 as a clinical antimicrobial or wound therapy" are different conversations. the science of LL-37 biology is genuinely rich, but rich science is not the same as a validated therapy.

safety profile and the paradox

acute tolerability has generally been favorable in the small clinical and animal datasets to date, but the pro- vs anti-inflammatory paradox creates real safety nuance. LL-37 can drive inflammatory and prothrombotic programs in some disease contexts and has bidirectional associations in cancer biology. long-term controlled human safety data do not exist.

the paradox is the single most important safety teaching point. LL-37 is not a passive anti-microbial peptide; it is a host-response coordinator that can amplify or suppress inflammation depending on local conditions. in sepsis and endotoxemia models it can improve outcomes by neutralizing endotoxin and reducing TNF-alpha amplification, but in autoimmune and prothrombotic settings it can drive harmful inflammation, NET-related signaling, and immune complex formation.

on the cancer side the same bidirectionality applies. LL-37 has reported tumor-suppressive activity in some epithelial cancers and tumor-promoting activity in others, and which direction wins is tissue-specific and context-specific. product-quality variability in grey-market sources adds an additional safety layer that is not specific to LL-37 but matters because LL-37's pharmacology is dose- and context-sensitive in ways that benign quality assumptions can hide.

where it fits in peptide therapy

LL-37 occupies a distinctive slot: a native human antimicrobial peptide with an exceptionally broad activity portfolio and the closest mechanistic link between vitamin D status and innate antimicrobial defense. it is conceptually distinct from receptor-defined therapeutic peptides like the GLP-1 family or GHRH analogs, and it overlaps most usefully with the broader antimicrobial peptide and host-defense peptide landscape.

relative to receptor-defined therapeutic peptides such as semaglutide, tirzepatide, and the GHRH analog tesamorelin, LL-37 is not a receptor agonist in the conventional drug-development sense. its primary site of action is the microbial membrane and its secondary axis is FPR2-driven leukocyte recruitment plus broad immunomodulation. that makes it harder to develop as a single-target drug and easier to develop as a topical or local-delivery host-defense tool.

relative to other peptides studied for tissue repair and antimicrobial work, the comparison is less direct because LL-37 is the single human cathelicidin, whereas most peptide-based wound and gut tools belong to entirely different families. for adjacent tissue-repair peptide biology, BPC-157 is the most-studied non-host-defense comparator in community contexts; for the GI inflammation angle, our KPV page covers the alpha-MSH-derived tripeptide story. the broader pathway tour is in our free how peptides work module.